Spellacy W N, Buhi W C, Dumbaugh V A, Birk S A
Fertil Steril. 1978 Sep;30(3):289-92. doi: 10.1016/s0015-0282(16)43513-2.
Forty-four women were prospectively evaluated with a 3-hour oral glucose tolerance test while they used a new weekly oral contraceptive drug, R2323. The blood tests were carried out before the drug was administered and again 3 months after its use. Both blood glucose and plasma insulin levels were measured. In the 40 women with a "normal" control glucose tolerance test, it was found that only the 1-hour blood glucose value was significantly elevated after 3 months of drug use and the plasma insulin values were unchanged. The tests of three of the four women with borderline abnormal to abnormal control test curves converted to normal with 3 months of treatment and that of one remained unchanged. The fasting plasma cholesterol and triglyceride levels were unchanged over the 3 months' time. These results suggest that this steroid contraceptive has no effect on lipid metabolism. It also has minimal adverse effects on normal carbohydrate metabolism and may possibly improve abnormal metabolism.
44名女性在使用新型每周一次口服避孕药R2323期间接受了3小时口服葡萄糖耐量试验的前瞻性评估。血液检测在给药前及用药3个月后再次进行。同时测量血糖和血浆胰岛素水平。在40名糖耐量试验“正常”的女性中,发现用药3个月后仅1小时血糖值显著升高,而血浆胰岛素值未改变。4名糖耐量试验曲线边缘异常至异常的女性中,3名经3个月治疗后转为正常,1名未改变。在3个月的时间里,空腹血浆胆固醇和甘油三酯水平未发生变化。这些结果表明,这种甾体避孕药对脂质代谢无影响。它对正常碳水化合物代谢的不良影响也最小,并且可能改善异常代谢。